GOT1 and metabolic dysfunction-associated steatotic liver disease: HFD-induced obesity and abnormal lipid metabolism are associated with nonalcoholic fatty liver disease leading to hepatic failure and causing a boost in serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) levels in the serum [43].